DJIA 16,501.65 0.00 0.00%
NASDAQ 4,148.34 0.00 0.00%
S&P 500 1,878.61 3.22 0.17%
market minute promo

Verastem, Inc.

NASDAQ: VSTM

8.47 -0.21 (-2.42%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

VSTM $8.47 -2.42%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $8.73
Previous Close $8.68
Daily Range $8.15 - $8.73
52-Week Range $8.15 - $18.82
Market Cap $218.7M
P/E Ratio -4.77
Dividend (Yield) $0.00 (0.0%)
Volume 247,471
Average Daily Volume 186,685
Current FY EPS -$1.92

Sector

Healthcare

Industry

Drugs

Verastem, Inc. (VSTM) Description

Verastem Inc is a biopharmaceutical company focused on discovering and developing proprietary small molecule drugs targeting cancer stem cells along with proprietary companion diagnostics. Website: http://www.verastem.com/

News & Commentary Rss Feed

Verastem: Cancer May Have Met Its Match

Verastem Becomes Oversold (VSTM)

Verastem's CEO Discusses Q4 2013 Results - Earnings Call Transcript

Verastem Reports Data from Phase 1 Study of VS-6063 (defactinib) in Japanese Patients; Completes Ful

Verastem Reports Data from Phase 1 Study of VS-6063 (defactinib) in Japanese Patients; Completes Full Enrollment and was "Well Tolerated" at Each Dosage Level

Today's Biggest Biotech Stories: BioCryst, Verastem, and InterMune

BioCryst, Verastem, and InterMune could all loom large in health care headlines this morning. Here's why.

Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718

Verastem (VSTM) Jumps: Stock Adds 10.8% in Session - Tale of the Tape

Galena Biopharma: 3 Different Insiders Have Sold Shares This Year

Keep an Eye on Geron, Novartis, Cell Therapeutics, and Verastem Today

Geron, Novartis, Cell Therapeutics, and Verastem could make health care headlines this morning. Here’s why.

Verastem Initiates Phase 1 Trial of Dual mTOR/PI3K Inhibitor

See More VSTM News...